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Abstract
Purpose To determine the effectiveness of a shared decision-making (SDM) tool versus guideline-informed usual care in
translating evidence into primary care, and to explore how use of the tool changed patient perspectives about diabetes
medication decision making.
Methods In this mixed methods multicenter cluster randomized trial, we included patients with type 2 diabetes mellitus and
their primary care clinicians. We compared usual care with or without a within-encounter SDM conversation aid. We
assessed participant-reported decisions made and quality of SDM (knowledge, satisfaction, and decisional conflict), clinical
outcomes, adherence, and observer-based patient involvement in decision-making (OPTION12-scale). We used semi-
structured interviews with patients to understand their perspectives.
Results We enrolled 350 patients and 99 clinicians from 20 practices and interviewed 26 patients. Use of the conversation
aid increased post-encounter patient knowledge (correct answers, 52% vs. 45%, p= 0.02) and clinician involvement of
patients (Mean between-arm difference in OPTION12, 7.3 (95% CI 3, 12); p= 0.003). There were no between-arm
differences in treatment choice, patient or clinician satisfaction, encounter length, medication adherence, or glycemic control.
Qualitative analyses highlighted differences in how clinicians involved patients in decision making, with intervention
patients noting how clinicians guided them through conversations using factors important to them.
Conclusions Using an SDM conversation aid improved patient knowledge and involvement in SDM without impacting
treatment choice, encounter length, medication adherence or improved diabetes control in patients with type 2 diabetes.
Future interventions may need to focus specifically on patients with signs of poor treatment fit.
Clinical trial registration ClinicalTrial.gov: NCT01502891.
Keywords Shared decision making ● Decision aids ● Patient–clinician communication ● Diabetes ● Patient-centered care
Background
Over the last few decades, there has been an increasing call
for care to be more patient-centered and for patients to be
more involved in their care [1, 2]. One way of achieving this
is for patients and clinicians to engage in shared decision
making (SDM) [3]. In SDM, patients and clinicians work
together to understand the patient’s situation and determine
how best to address it [4].
How to review and use evidence to shape the clinical
response to the patient’s situation remains a key challenge
in the implementation of SDM in practice [5]. Evidence
suggests that SDM tools designed for use within the clinical
encounter by patients and clinicians—sometimes called
conversation aids—can support sharing evidence, improv-
ing patient knowledge, and facilitating SDM [6]. When
properly designed, these tools only contain the information
necessary, ideally from a systematic and up-to-date evi-
dence summary, to support the patient–clinician conversa-
tion [7, 8]. Clinicians and patients, working together, can
* Nilay D. Shah
Shah.Nilay@mayo.edu















draw from this information to co-create a treatment plan that
makes sense and responds well to the patient’s situation.
We previously developed a within-encounter SDM tool,
the Diabetes Medication Choice, to help patients with type
2 diabetes and their clinicians decide about diabetes medi-
cation [9]. In two pilot randomized trials vs. usual care, the
use of this tool improved patient knowledge, patient
involvement in decision making, and patient comfort with
the decision made [10, 11]. However, these trials did not
show improvement in glycemic control. This may have
been due to a lack of effectiveness of SDM, or to an
inability to find that effect either because these trials were
not powered to assess these outcomes or because the
population selected had limited chance to improve given
that they were relatively healthy, highly educated, and
demonstrated high treatment adherence [10, 11]. Possibly,
larger trials enrolling more diverse populations may provide
a better opportunity to assess the downstream effects of
support SDM and more generalizable evidence of the
impact of conversation aids such as the Diabetes Medication
Choice in translating evidence into patient-centered care
and outcomes.
The aim of this study was to determine the effectiveness
of the Diabetes Medication Choice SDM conversation aid
versus guideline-informed usual care in translating evidence
about diabetes medications into routine primary care. Also,
in order to better understand personal factors that might
underpin SDM conversations, we explored patients’ per-




We conducted a practical mixed methods cluster (practice)
randomized trial, comparing the use of the Diabetes Medi-
cation Choice conversation aid (intervention) to guideline-
informed usual care in primary care practices among
patients with poorly controlled type 2 diabetes (Clin-
icalTrial.gov: NCT01502891). The Mayo Clinic Institu-
tional Review Board, along with the boards of participating
sites, approved the study (#10-006952).
Randomization
We paired practices according to their numbers of clinicians
(≤2 vs. >2) and prevalence of diabetes in their practice
(self-rated as high vs. low). The study statistician randomly
allocated practices to the intervention or usual care
after practices had been enrolled, ensuring allocation
concealment. Practices, clinicians, and investigators were
aware of the assigned arms.
Intervention and usual care
The intervention consisted of the use of the Diabetes
Medication Choice conversation aid by patients and clin-
icians during the clinical encounter. This tool presents
general considerations and adverse effects of diabetes
medication, organized in terms by topics that matter to
patients: weight change, daily routine, blood sugar levels
(HbA1c), daily blood sugar testing, hypoglycemia, and cost.
The latest version of the tool is freely available at https://dia
betesdecisionaid.mayoclinic.org/. Each topic occupies a
card that the patient and clinician review as needed, with
both negotiating which ones to review, in what order, and in
what detail, until they arrive at a preferred approach by
consensus. Patients could take home a one-page handout
version of the conversation aid. Clinicians received training
on how to use the conversation aid during a 10 min group
session (including rationale, demonstration of use, role
playing), by accessing an online demonstration and a one-
page storyboard, and by requesting ad-hoc, one-on-one
training during the study.
Usual care consisted of clinicians engaging with their
patients as usual with an increased awareness of diabetes
care guidelines. To that end, we provided clinicians with
copies of the Institute for Clinical Systems Improvement
diabetes care algorithm, a set of guidelines promoted by
health plans in Minnesota, and the American Diabetes
Association-International Diabetes Federation expert algo-
rithm to assist in in choosing an antihyperglycemic agent
[12]. These informational resources were also provided to
clinicians in the intervention group.
Participants and setting
This study took place between July 2010 and May 2014
across 20 rural, suburban, and inner-city primary care
practices from six health systems in the Midwest (Minne-
sota, Wisconsin), United States. All clinicians in partici-
pating practices caring for patients with type 2 diabetes
were eligible to participate. Patients were eligible if they
were an adult with a clinical diagnosis of type 2 diabetes
mellitus, a recent (<12 months) HbA1c measure greater
than 7.3% (selected by consensus to represent a level above
the recommended 7% target HbA1c at the time of the trial),
not receiving insulin (to indicate that they had several
treatment options available to improve glycemic control,
including insulin), a pre-scheduled appointment with a
primary care clinician participating in the study, no intel-
lectual or sensorial barriers to providing written informed
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consent, and available for the duration of follow-up
(12 months).
Procedure
We identified potential practices from public listings of
regional practices and approached either the medical
director or a pre-identified clinical champion to seek interest
in participation. If interested, we presented the study at their
on-site staff meeting. If the practice agreed to participate,
we immediately recruited clinicians at this meeting and, in
addition, individually approached clinicians. On-site study
coordinators then identified potential eligible patients and
contacted them either via phone or in-person immediately
preceding their scheduled appointment to gauge interest in
participating. All participants provided written informed
consent.
We collected participant demographics at time of con-
sent. With permission, we video-recorded patient–clinician
encounters. We asked patients and clinicians to complete a
paper survey immediately following the encounter, and we
asked patients to complete follow-up paper surveys 2, 6,
and 12 months after the encounters. Lastly, we reviewed
patients’ medical records at baseline, and at 12 months after
the encounter to collect information about hemoglobin A1c
and use of diabetes medications. Patients were also asked to
provide consent for the research team to contact the phar-
macy where the patients usually fill their medication pre-
scriptions to document dates of medication fills.
At baseline, we invited and consented patients to parti-
cipate in an interview, which took place at a later date either
in-person in the clinic or by telephone, based on the
patient’s preference. Interviewers contacted consenting
patients for scheduling, aiming to balance the interviews by
study arm. We aimed to conduct interviews as soon after the
clinic visit as possible, to promote more accurate recall.
Interviews were recorded with permission, transcribed
verbatim, and checked against audio files for accuracy.
Measures
Decision and quality of decision-making
In the post-encounter survey, patients reported whether a
discussion about diabetes treatment occurred and, if so,
what decision was made (e.g., increase medication dose,
change, or add a medication). They also completed six true/
false knowledge items about the treatment options and their
pros and cons [10, 11, 13], our primary SDM outcome,
three of the five subscales of the Decisional Conflict Scale
(perceived knowledge, support, and effectiveness) [14], and
two items on satisfaction with the information shared [11].
Clinicians’ post-encounter survey consisted of one item
on satisfaction with decision making [10, 11]. Clinicians in
the intervention arm also answered two questions about the
ease of incorporation the conversation aid into the
encounter.
From the recordings of encounters, we assessed the
extent to which clinicians engaged patients in the decision-
making process, using the 12-item Observing Patient
Involvement in Decision-Making (OPTION) scale [15]. We
also assessed the extent to which clinicians covered the
topics described in the conversation aid in both intervention
and control arm, using an 11-item fidelity checklist. We
considered adequate fidelity when patients and clinicians
covered >7 items [11, 16]. Finally, we noted the length of
the encounter.
Clinical and adherence outcomes
Our primary clinical outcome was the proportion of patients
having reached a level of hemoglobin A1c (HbA1c) of
<7.3%. We used the HbA1c measure that had been taken at
the closest point in time to the final follow-up visit
(12 months from enrollment) that was available in the
medical record. We calculated, from pharmacy records,
primary adherence as the proportion of patients who filled
their prescription of antihyperglycemic medications within
30 days of the index encounter, and secondary adherence
(i.e., persistence) as both the average of percentage of days
covered (PDC) and the proportion of patients with a PDC
>80% [17]. PDC was defined as the number of days a
patient had a supply of each medication divided by the
number of days of eligibility for that medication, for each
antihyperglycemic medication prescribed [17].
Patient interview
Two members of the study team (JL and KT) completed the
patient interviews using a semi-structured interview guide
developed using Normalization Process Theory (NPT) as a
guiding framework [18]. NPT focuses on the implementa-
tion of complex interventions in healthcare. For this study,
NPT constructs informed questions about the work patients
do to manage their health and make decisions about care
[19]. The goal of this qualitative part of the study was to
shed light on patient chronic disease management, which
includes interactions with the healthcare team for patients in
both study arms. We asked patients in the intervention arm
additional questions about satisfaction with the conversation
aid and its role in decision making. For in-person interviews
with patients whose clinical encounter was recorded, the
interviewer played a short clip of the encounter. The
interview guide is included as Appendix A.
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Sample size
We sought to estimate the effect of the intervention on
patient knowledge, HbA1c, and adherence. We expected
that 40% of patients in the usual care arm would reach a
HbA1c ≤ 7.3 and established through consensus that, for
the intervention to be considered a success, we would
require at least 55% of patients in the intervention arm to
have reached this target [20]. In order to detect an
increase of 15% in the intervention arm at a significance
level of 0.05 and 80% power with a two-sided t test and a
correlation of outcomes [intracluster correlation coeffi-
cient (ICC)] within practices of 0.025 (estimated from the
DAD (decision aids to enhance SDM for diabetes) trial
using the same intervention [11]), we estimated that we
would need 660 patients (30 patients per practice, 22
practices total) [21]. Under similar assumptions, we cal-
culated that this sample size had a 99% power to detect
one standard deviation difference in any continuous
measure (i.e., knowledge), and 80% power to detect a
30% difference in 12-month adherence rates (assuming a
control adherence rate of 50%).
For the qualitative part of the study, we aimed to include
two patients per participating practice. Interview sampling
and data collection occurred iteratively with analysis. The
study team met regularly to discuss emergent findings and
assess the need for additional data. We stopped the sam-
pling and interviews when the study team found no new




The study adhered to the intention-to-treat principle,
with patients and clinicians kept and analyzed in the arm
to which they were randomized regardless of the inter-
vention received. Patients without an assessment of their
HbA1c during the 12-month window following the index
encounter were considered to have not met HbA1c
<7.3%; patients without adherence data were considered
to have not met the 80% PDC cutoff. For all other out-
comes, only complete data were analyzed. Sensitivity
analyses and adherence were also only conducted on
complete data. All analyses accounted for clustering (of
practice) in the study design. Patient and clinician
characteristics were compared between randomization
arms using the cluster-adjusted t tests and chi-
square tests.
For unadjusted comparisons of outcomes, we used
cluster-adjusted t tests and chi-square tests, and for all
adjusted analyses we used hierarchical generalized linear
models [21]. These statistical methods address the unit of
analysis issue through terms for each level of grouping or
clustering. Also, these models account appropriately for
clustering of patients within clinicians and practices and
allow us to deal with repeated observations of patients.
Analysis was conducted using SAS software 9.4 and
Stata 14.0 [22, 23].
Qualitative analysis
Three investigators of the study team (JL, JR, and KT)
analyzed transcripts of interview recordings using a fra-
mework approach. First, investigators familiarized
themselves with the data and began to identify key issues
and conceptualize a thematic framework, which included
a priori topics from the interview guide. The analysis
team identified talk about how patients perceive their
ability to engage in SDM as an important theme, and they
refined the framework to include patient competencies
reported in literature about informed shared decisions
(e.g., capacity to define and establish relationships with
clinicians, articulate problems, access and evaluate
information, and negotiate decisions with clinicians)
[24]. The framework was systematically applied to tran-
scripts by at least two investigators, with discrepancies
discussed until consensus was reached.
Transcripts were entered into NVivo 12.0 to facilitate
queries and analysis, which involved charting the data
thematically by study arm (using a coding matrix) and then
returning to the study questions during interpretation.
During this stage the investigators also checked for differ-
ences related to conversation aid use.
Results
Participants
A total of 350 patients from 20 practices were enrolled from
February 2011 through June 2013. Enrollment ended before
meeting the recruitment goal due to slower than anticipated
accrual.
Twenty-two sites were invited and agreed to partici-
pate. Two sites withdrew after being randomized (one in
each study arm), due to changes in staffing within each
practice. A total of 495 patients were initially assessed as
eligible and were approached for study participation (Fig.
1). Of these, 350 (71%) participated, 189 in the inter-
vention arm, and 161 in the usual care arm. A total of 99
clinicians participated in the trial, four of them seeing
patients at two sites for a final total of 103 clinicians. All
patient and clinician characteristics were balanced across
arms (Table 1). Appendix B reports the results of the 2-
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and 6-month patient surveys (on reuse of the Diabetes
Medication cards, recall, and adherence to the decision
and to the medicines).
We completed qualitative interviews with 26 patients (11
in usual care arm, 15 in intervention arm). Patients’ ages
ranged from 35 to 73 years (mean 59), and ten (39%) were
female. The average length of the interviews was 27 min
(range 12–44 min), the median time between the index
encounter and the interview was 42 days (range
9–137 days).
Decision and quality of decision-making (Table 2)
Clinicians allocated to the intervention arm reported
using the conversation aid in 86% of the associated
encounters. Of the list of 11 topics expected to be covered
as part of an SDM conversation, 68% of recorded inter-
vention encounters and 42% of usual care ones completed
>7. Nearly all patients in both arms made a decision to
either continue their current medications or to add a new
medication, with only 4.9% in the usual care arm and
6.9% in the intervention arm remaining unsure or unable
to make a decision. Use of the conversation aid did not
significantly alter treatment decisions.
The use of the conversation aid increased post-
encounter patient knowledge (correct answers, 52% vs.
45%, p= 0.02). No significant between-arm differences
were found in patients’ perception of being informed (p
= 0.10) or supported (p= 0.90), having made a good
decision (p= 0.96), or being satisfied with the informa-
tion given (p= 0.15). Use of the conversation aid sig-
nificantly increased clinicians’ effort to involve patients
in decision making (mean difference in OPTION12
scores across arms, 7.3, 95% CI 3, 12; p= 0.003). The
encounters in both arms were of similar duration (26 min
with decision aid vs. 28 min without, p= 0.64).
There was no significant difference in clinician satis-
faction between arms. Clinicians in the intervention arm
reported the conversation aid was (very) easy to use (86%
of encounters) and (very) easy for their coworkers to
incorporate it into their workflow (63%).
Fig. 1 Study flowchart
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Clinical outcomes and adherence
Compared to usual care, the use of the conversation aid did not
improve glycemic control (HbA1c ≤ 7.3 usual care 20% vs.
26% conversation aid; p= 0.32) or medication adherence
(PDC 89% vs. 94%, p= 0.15; PDC > 80% 81% vs. 87%; p=
0.5) at 12 months from the index encounter (Table 2).
Patient interviews
We summarized findings from the qualitative patient inter-
views in two themes that portray patient perspectives on
decision making. They are described below using the lens
of patient competencies, focusing on knowledge, skills or
abilities that patients need to engage in SDM [24]. The
competencies reflected most clearly in our data include the
ability to systematically articulate the problem and expec-
tations, and the ability to negotiate decisions.
Articulating the problem and expectations in a systematic
manner
Patients in both study arms described communicating their
health concerns to clinicians, including symptoms of high
blood sugar levels, and they gave examples of “good” doctors
who explained medications to them and answered any ques-
tions they had. In the intervention arm, patients provided
Table 1 Participant characteristics




Average per site 16 17
Age, mean (SD) 62 (12) 59 (11)
Female, N (%) 86 (53) 72 (38)
BMI, mean (SD)a 36 (7.3) 36 (8.9)
Race, N (%)
White 139 (86) 155 (82)
Black 14 (9) 24 (13)
Other 8 (5) 10 (5)
Insurance, N (%)b
Employer/Union 69 (49) 73 (47)
Direct from insurance
company
16 (11) 21 (14)
Medicare 30 (21) 33 (21)
Medicaid 13 (9) 23 (15)
Tricare/military 2 (1) 0 (0)
Other 10 (7) 4 (2)
Education, N (%)b
High school or less 50 (35) 66 (42)
Vocational/4-year
college degree
84 (59) 76 (49)
Graduate degree 8 (6) 14 (9)
Adequate literacy, N
(%)b
24 (17) 21 (13)
HbA1c, mean (SD) 8.9 (1.2) 8.9 (1.4)
HbA1c, N (%)
<7.5% 14 (9) 11 (6)
7.5 to <8.0% 34 (21) 37 (20)
8.0 to 8.5% 25 (16) 48 (25)
>8.5% 88 (55) 93 (49)
Years with diabetes, N (%)b
<5 38 (27) 49 (31)
5 to <10 53 (38) 58 (36)
>10 49 (35) 53 (33)
Years with clinician, N (%)b
<1 31 (22) 30 (18)
1 to <5 33 (24) 51 (31)
5 to <10 23 (16) 41 (25)








Mean (SD) 5.3 (3.5) 4.8 (3.8)
Median (Q1–Q3) 5.5 (2–7) 4 (3–5)
Age, mean (SD)c 45 (12) 45 (11)
Female, N (%) 27 (51) 26 (54)
Practice, N (%)
Family medicine 44 (83) 36 (75)
Table 1 (continued)




Internal medicine 9 (17) 11 (23)
Other 0 (0) 1 (2)
Clinician Typed, N (%)
Physician (MD, OD) 46 (87) 39 (77)
Advance practitioner
(PA/NP)
6 (11) 7 (15)
Years in practice, mean
(SD)d
12 (12) 12 (910)
Patients in panel with diabetes, N (%)e
<25% of the panel 30 (57) 29 (60)
25–50% 15 (28) 12 (25)
>50% 5 (9) 2 (4)
Number of encounters,
mean (SD)
3 (3) 4 (3)
aUsual care N= 144, Conversation aid N= 170
bSelf-reported by patients, missing responses are not represented in
counts or percentages.
cUsual care: N= 51, Conversation aid: N= 43
dUsual care: N= 52, Conversation aid: N= 44
eUsual care: N= 50, Conversation aid: N= 43
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Table 2 Participant-reported and observed encounter outcomes
Outcomes
(Usual care N/Conversation aid N)
Usual care Conversation aid Mean difference
DA-UC (95% CI)
ICC P value
Decision made N (%) N (%) 0.107 0.95
Start new/continue medication 22 (14) 37 (19.6)
Start new medication only 42 (26) 39 (21.6)
Continue medication only 88 (55) 98 (51.9)
Not start new (medication naïve) 1 (1) 2 (1.1)
No decision made/unsure 8 (5) 13 (6.9)
Quality of decision making Mean (95% CI) Mean (95% CI)
Knowledge (141/166), % correct 45 (42, 49) 52 (49, 55) 6.2 (0.004, 12.0) 0.025 0.04
DCS informed (134/158) 19 (16, 22) 15 (12, 17) −4.4 (−9.6, 0.9) 0.033 0.10
DCS support (134/157) 15 (13, 18) 15 (13, 18) −0.2 (−4.3, 3.8) 0.005 0.90
DCS effective (130/152) 15 (12, 18) 15 (12, 17) −0.01 (−5.7, 5.1) 0.051 0.91
Patient satisfaction, N (%)
With information re medication (128/151) 113 (88) 142 (94) ~ 0.022 0.15
With conversation (129/152) 124 (96) 146 (96) ~ 0 0.98
Video-analysis outcomes Mean (95% CI) Mean (95% CI)
OPTION12 (48/96) 17 (15, 20) 25 (23, 27) 7.3 (2.9, 11.8) 0.063 0.003
Covered >7 of 11 items (48/96) 42 (35, 49) 68 (63, 73) 25.8 (14.5, 37.2) 0.065 <0.001
Encounter duration, min (137/172) 28 (20, 37) 26 (16, 35) −2.7 (−14.5, 9.1) 0.326 0.64
Glycemic control
HbA1c at 12 months, mean (SD)a 8.4 (1.7) 8.1 (1.5) 0.33 (−0.10, 0.76) 0.009 0.13
≤7.3%, intention-to-treat, N (%)b 33 (20) 50 (26) ~ 0.033 0.32
≤7.3%, complete data only, N (%) 33 (26) 50 (33) ~ 0.058 0.43
Adherence to medications
Mean PDC (SD)c 89% (19) 94% (12) 5.0% (−2.0, 12.0) 0.064 0.15
PDC > 80%, intention-to-treat, N (%)b 67 (42) 80 (42) ~ 0.124 0.95
PDC > 80%, complete data only, N (%) 67 (81) 80 (87) ~ 0.116 0.49
by baseline HbA1c, N (%)
<7.5% 6 (86) 2 (50) ~ 0.446 0.26
7.5–7.9% 10 (83) 11 (85) ~ 0.377 0.95
8.0–8.5% 12 (86) 20 (91) ~ 0.175 0.69
>8.5% 39 (78) 47 (89) ~ 0.152 0.36





Satisfied with discussion, N (%) 133 (86) 155 (88) 0.14
Used conversation aid, N (%)d 0 (0) 151 (86) ~
Aid was (very) easy to use, N (%)e 130 (86) ~
Aid was (very) easy to integrate in work
with coworkers, N (%)
95 (63) ~
DCS Decisional Conflict Scale, SD Standard Deviation, PDC Percentage of Days Covered
aAnalysis of complete data only
bIntent to treat analysis where missing observations were treated as >7.3 or adherence ≤80%
cIncludes all patients for whom a pharmacy record was received (N= 175; UC= 83)
dMissing nine responses in Usual care, 1 in Conversation aid
eMissing 12 responses
Bold values indicate significance at the 0.05 level
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more and more specific examples of information sharing
during the encounter, compared to more general comments
about issues like side effects in the usual care arm.
The following two patients demonstrate some of the
identified differences in intervention and usual care arm
conversations. Patient 14 talked about getting support from
his clinician and his daughters, but ultimately, he felt he just
needed to better follow through with his clinician’s advice to
lose weight. His quote (Table 3, 1a) exemplifies the fact that
he usually knows how the clinical conversation is going to
play out. Patient 6 provided a contrasting example of sharing
information in the encounter (Table 3, 1b). She spoke about
how the conversation aid helped her talk with her clinician
about medication costs. In fact, she thought the tool provided
education for both of them.
Negotiating decisions
Patients in both study arms described negotiating decisions in
the clinical encounter, especially making an argument when
they wanted to try a strategy a little longer before increasing a
medication dose or going to an injectable. They often placed
these discussions in the context of on-going negotiations with
the clinician on these topics. Patient 16 described a 3-month
window that he had previously requested, which at this visit
was extended another 6 months (Table 3, 2a). Patient 13
described the open communication she has with her clinician,
including discussion of her preferences (i.e., refusal to go on
insulin). Still, when it came to the medication decision, she
largely left it to her clinician (Table 3, 2b).
Patients in the intervention arm described similar compe-
tencies in negotiating disease management decisions but they
also described the role that the conversation aid had when
focusing the conversation on the most important decision-
making factors. Patient 2 referenced prior negotiations (“I had
told her that I did not want to take insulin injections. She knew
that from previous doctor appointments.”) but then went on to
describe how her clinician used the conversation aid to talk
about other options (Table 3, 2c). Patient 1 described her use
of the conversation aid outside of the encounter. She reviewed
the side effects information on the tool with her clinician and
decided not to make a change. A few days later, though, she
reviewed it again and then called her clinician to say she was
ready to make a change.
Table 3 Selected quotes from
patient interviews Articulating the problem and expectations in a systematic manner
1a “Sometimes, I tell the doctor I think I am taking too many. He just looks at me and ‘Mhmm. Exercise,
exercise’”.
(Patient 14 (male), usual care)
1b “I know that we talked about the cost of some of these. you know she mentioned the fact that this is a
really good med, but it’s also $9 a day to use. So you know, right now I’m using Metformin and it’s
seems to be doing the job. At a dime a day so, what do you do? [The conversation with the SDM tool]
was a little bit different because we kind of used these cards and there was some kind of a little survey
about what was the most important… I don’t think she was aware of how expensive meds are. Um, she
just prescribed a cream for like a heat rash. And it was a little 4 ounce tube, it was $40. I asked her
before the conversation ‘How much do you think that costs?’ and she said ‘Oh, probably $5’ and it was
$40 so, I don’t know that doctors realize how expensive this stuff is”.
(Patient 6 (female), intervention)
Negotiating decisions
2a “So, my levels were kind of high and at that time he had talked about increasing my level of
medications. And so I told him I needed….he gave me 3 months to try to get it back under control.
Which I did….You know, I’m the one that is in control, because I know what I need to do. I just need
to do it”.
(Patient 16 (male), usual care)
2b “Oh, yah…yah. She knows that I will. [Laughs] I am very blunt. Blunt about what I want and what I
don’t want. She knows. She’s very—she is also very blunt in telling me what I need. We kind of go
back and forth.” […] Well, she just kind of made that decision. And, she said that she wanted me to try
the Glyburide because I have been refusing to go on insulin, because I don’t want to go on insulin…so
she told me—I think she gave…she said, like, a couple different medications and then she decided on
the Glyburide”.
(Patient 13 (female), usual care)
2c “Well, the three things I picked out was cause, side effects, and I can’t remember the third one I picked
out. But then she recommended that one medicine and I said, yah, I’d consider taking that one because
it was a tablet form; it wasn’t injection. And it could be added to—in addition to the medicine I take
now. It would be another tablet—another medicine… and there wasn’t many side effects that I was
concerned about where other medicine you gain weight, you have dizziness and nauseating and I
didn’t want any of that”.




We found that the use of the Diabetes Medication Choice
SDM conversation aid by patients with type 2 diabetes and
their clinicians during primary care encounters promoted
patient knowledge and clinicians’ effort to involve patients in
decision making, without adding to the length of the
encounter. However, the use of the conversation aid had no
significant effect on satisfaction, treatment selection, adherence
to treatment, or glycemic control. Qualitative analyses high-
lighted differences in the way clinicians involved patients in
decisional conversations, and patients using the conversation
aid were able to articulate what they learned about different
medications as their clinician led them through a conversation
focused on factors important to them.
Strengths and limitations
This study has some limitations. We did not reach our targeted
sample size and there was substantial missing data resulting in
loss of precision. Funding affected the completion of the trial
as planned and the timely reporting of its findings. Despite
enrolling a more diverse population, as in our previous trials,
participants had high adherence at baseline and limited room
to improve their glycemic control. And yet, the mean HbA1c
in both arms at study end was >8% and fewer than a third of
participants achieved HbA1c < 7.3%. Patients and analysts
were not blinded to the intervention which may have biased
survey responses and analysis of video recordings, including
scoring of the OPTION12. Strengths of this trial included its
pragmatic randomized design, implementation of allocation
concealment, implementation of the intervention in usual pri-
mary care settings, analyses accounting for clustering, and
magnitude of results comparable to previous efficacy trials.
Implication for practice, policy, and research
Our findings leave our trial question open. In the time that has
elapsed since the conclusion of this trial, important develop-
ments have changed the landscape of diabetes care, including
the emergence of new agents which differ from the ones
available at the time of trial in their cost, administration routes,
and side effects including ability to cause hypoglycemia and
weight gain. These options reduce the risk of adverse cardio-
vascular and renal events, outcomes that patients find important
[25]. Furthermore, regional guidelines and quality measures
have been liberalized to account for the evidence about the
impact of glycemic control in patients with type 2 diabetes and
the harms associated with overtreatment [26]. Remote care
approaches such as telemedicine have become mainstream with
the COVID-19 pandemic, and yet little is known about the
feasibility and effectiveness of remote SDM approaches [27].
That there are more ways of caring and that the tools used in
this study require little clinician training and no patient pre-
paration may all contribute to promote SDM in diabetes care
even where this expectation may be just evolving [28]. Also, it
has become clear that adherence as an outcome measure is, like
for other outcomes, quite sensitive to the prevalence of non-
adherence at baseline [29]. At the same time, conducting a trial
in patients with poor treatment fidelity at baseline poses sub-
stantial challenges. For example, patients’ decision to partici-
pate in a trial, and their fidelity to participation test some of the
same processes that contribute to treatment adherence. New
minimally disruptive research methods may need to be devel-
oped and implemented to better test interventions seeking to
improve the care of patients struggling to implement treatment
work with limited capacity to do so [30].
Finally, the care of patients with diabetes is evolving
towards “whole-person care” in response to the increased
recognition of their substantial personal and biological com-
plexity [31]. As patients struggle with multimorbidity, social
isolation, and treatment burden, it is important to build treat-
ment programs that can be weaved into the challenging lives
of these patients. Thus, SDM becomes less about choosing a
drug and more about co-crafting a treatment program so that it
can solve the problems the patient faces in a manner that
makes intellectual, emotional, and practical sense to that
patient [32]. Our team has proposed the notion that in these
patients, SDM is not about making choices but about
addressing the problematic situation of patients [33]. In this
way, SDM joins other approaches clinicians can use, including
minimally disruptive medicine [34], to improve the effective-
ness of diabetes care by making care fit. Subsequent efforts to
assess the value of SDM in the care of patients with diabetes
may therefore need to select patients for whom usual care
approaches (target driven, mechanistically or algorithmically
directed) fail (e.g., patients with poor glycemic control, low
treatment satisfaction, low treatment fidelity) and test the value
of “problem-solving” SDM [33]. This manner of care would
involve a toolkit of approaches that work together to help the
patient and clinician in defining which aspect of the patient’s
situation requires action and which action that situation
requires. Outcomes may need to include not just glycemic
control parameters, which are insensitive to the benefits of
specific diabetes agents, but also the human quality of care and
the degree of fit the treatment exhibits in patients’ lives.
Conclusions
An implementation in primary care of an SDM conversation
tool about diabetes medications was able to improve clinician
involvement of patients in diabetes care decisions and to
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improve patient knowledge without impacting visit duration
but this did not translate into changed treatments or improved
diabetes control or treatment adherence in patients with type 2
diabetes. The effectiveness question our trial asked remains
open. Our results strongly suggest methodological modifica-
tions to make subsequent trials more successful, for example
by focusing the intervention among patients who exhibit signs
of poor treatment fit, including low satisfaction with treatment,
high treatment burden, poor treatment fidelity, and poor dis-
ease control.
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Appendix A. Patient interview guide
Note that the goal of an open-ended “qualitative”
interview guide is to promote discussion around a pre-
determined set of content domains or topics [marked in
brackets]. The questions will be tailored to each parti-
cipant and thus the scripts presented here may be mod-
ified depending on the response of the interviewee. Each
domain is covered in the conversation between research
participant and interviewer. Probes (clarification ques-
tions) are used to make certain that the interviewer
understands the answers offered. Not every probe will be
asked. This style of interviewing is used when studying a
new area of inquiry where little previous research has
been done. One goal is to elicit concerns that were not
anticipated by the researchers.
N.B. The time allocated to each interview is ~30 min.
The length of the interview can vary depending on the
interviewee. This interview guide is intended to provide a
road map for the interviewer, but not all questions will be
asked in all cases, nor will all probes be used.
If the patient’s enrollment visit was videotaped, the
interviewer may ask the patient to view a vignette of the
patient–clinician encounter. “At your last visit, you
agreed to have it videotaped. I’d like to play a short part
of the video where your provider is showing you the
diabetes cards and discussing care options. We think this
will help remember the discussion. At any time we can
turn the video off”.
Introductions
Thank you for participating in the Diabetes study.
My name is xxx. I am a [medical anthropologist and]
qualitative researcher for Mayo Clinic. I will ask you a few
questions about your recent visit with your doctor. Is that okay?
In our study, we look at different ways to share infor-
mation about diabetes
medications so that we can improve the material. We are
especially interested what patients and doctors do when
they decide about choosing diabetes medications.
General questions
But, before I will be asking you a few questions about
your visit with your doctor, I have a few general points to
go through to make sure you are okay with the interview.
Do you have any questions about the study or the interview?
About the procedures we plan to use to protect your
confidentiality?
Do I have your permission to record our conversation?
If at any moment you would like to stop the tape, please let
me know. We can always stop it and turn it back on. Okay?
Thanks. [turn on tape]
Okay, let’s get started.
(1) [motivation] Have you been in research studies
before? Why did you decide to participate in this one?
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(2) What have you heard about the idea of using edu-
cational handouts or other materials to make decisions about
choosing medications?
(3) (USUAL CARE) Did your doctor give you educa-
tional/informational handouts or write down information for
you during your last visit?
Probe: What about showing you something on the
computer?
(3) (INTERVENTION) Did your doctor use the diabetes
medication choice cards with you at your last visit? Had you
seen something like this before?
Now, before we talk more about the cards and the
visit with your doctor, let’s talk a bit about how you like
to take care of your health:
(4) [Action] So first, can you tell me about your history
of diabetes (INSERT YEARS)? How did it start?
Probe: How do you cope with your diabetes on a
daily basis?
(5) What type of work do you do? Does that make it
difficult for you to manage your diabetes (med intake, food
intake, exercise?)
(6) Do you live alone? [AGE?].
Probe: Is someone helping you with your food prep/
medications?
(7) How many medications total do you take? Daily?
[from video, patient takes XX different medications and/or a
daily aspirin]
Probes: Do you also have a history of high blood pres-
sure? Do you have a history of high cholesterol?
We will now turn to some questions about health
decision-making:
(8) [Decision-making preference] What do you usually
do to help you make decisions about your health? Can you
give an example?
For example:
Do you read up online?
Do you talk to friends and family about it?
Do you talk to your doctor/health professional?
(8a) If you are unsure about what to do, how do you
ordinarily make a decision about your health? Example?
(9) Can you describe a typical medication discussion with
your doctor? Who, in your view, should be in charge?
(9a) When you think of your last visit, was the medication
discussion from your usual medication discussion with your
doctor?
(10) Do you feel that you can speak your mind when
discussing medication options with your doctor? Can you
give an example?
Probe: When discussing new medication options, do you
feel pressured into making the decision your doctor
recommends?
(11) [Participation in decision-making] How much gui-
dance or independence do you feel you need when making an
important decision about your health? Can you give an
example?
For example:
Do you like to discuss things with your doctor?
Do you want your doctor to tell you what to do?
Do you prefer to decide on your own?
(11b) [social network] Who would you say are the three
most important people involved in helping you to manage
your diabetes and stay healthy?
Probe: Explain. Why do you consider these three so
important?
(USUAL CARE) Now let’s talk a bit more about your
last visit with your doctor:
(12) [Action] You came to see your clinician about
INSERT DATE ago to do a checkup, blood tests etc. Can
you describe the visit in your own words?
(13) [sense-making] Can you tell me what you and your
doctor talked about? [adding a new med, increasing dose,
side effects, risks and benefits]?
(14) [sense-making] IF APPLICABLE ONLY
Did you discuss the possibility of XXX [ADJUST I.E.
adding a new medication]. What do you remember about
the different medications, their pros and cons?
Probes: Do you remember what s/he said?
Did s/he write anything down?
Did s/he give you options?
(15) Did you participate in the decision to the extent that
you wanted? How so?
(15a) [if applicable[Which medication did you add/
change? (INSERT MEDICATION NAME)
Probes:
Are you on it now? How do you feel about it?
Do you regret your decision to having added this parti-
cular medication? Explain.
(16) [sense-making] What in the medication discussion
helped you to decide whether you should take a different
diabetes medication?
(17) Do you remember any specific issues about medi-
cations that were discussed?
Probe: Weight loss, cost, schedule, etc. (Some medica-
tions can affect your weight, did you discuss this? What
about cost?)
(18) Were you able to accomplish what you had hoped to
do during this visit?
(19) [coherence/interaction] How would you describe
your relationship with your clinician?
(20a) Did you feel that you got adequate information
from your clinician about diabetes medications and their
potential risks and benefits? How so?
(20b) Did you feel that your clinician took enough
time to talk to you? Explain. (Visit lasted about XX
minutes)
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(20) Would you say you have changed anything about
how you take care of yourself since you came to see your
doctor in DATE?
Probe: If yes, what have you changed?
If no, do you plan to change anything about how you
take care of yourself? What?
(21) [social network] Do you talk about your diabetes
medications with your friends and family?
Probes: Why? Why not?
What do you talk about?
(22) [appraisal] Is there any way you regret how your last
clinic visit went? Explain.
Probe: Would you have wished the visit would have
gone differently? Explain.
(23) Is there anything you would like to add? Any topics,
you feel, I should have addressed?
Thank you for your time. You can now choose between
these two cookbooks as a little gift for your participation in
this study…
Follow-up: We plan to call you again in a few months
for a follow-up over the phone. Is that okay?
Please feel free to contact the Mayo Clinic study coor-
dinator or myself if you have any questions about this study.
My Mayo phone: 507-XXX-XXXX
(INTERVENTION) Now let’s talk a bit more about
your last visit with your doctor:
(12) [Action] You came to see your clinician about
INSERT DATE ago to do a checkup, blood tests etc. Can
you describe the visit in your own words?
Probe: What did you talk about?
What were issues that came up?
(13) [sense-making] Our records indicate that you used a
diabetes decision making tool at your clinic visit. What do
you remember about it [show patient tool. Let patient look
at and play with it while talking]?
Probes: Can you tell me what you and your doctor
talked about when looking at the tool [side effects, risks
and benefits]?
Do you remember what s/he said?
Did s/he write on it?
Did s/he hand this to you?
(14) [sense-making] So when you looked at this tool, did
it make sense to you?
Probes: Was it easy/hard to understand? Explain.
(15) [sense-making] IF APPLICABLE ONLY
Did you discuss the possibility of XXX [ADJUST I.E.
adding a new medication]. What do you remember about
the different medications, their pros and cons?
Probes: Did you participate in the decision to the extent
that you wanted? How so?
(15a) [if applicable[Which medication did you add/
change? (INSERT MEDICATION NAME)
Probes:
Are you on it now? How do you feel about it?
Do you regret your decision to having added this parti-
cular medication? Explain.
(16) [sense-making] Would you say that the tool helped
you to decide whether you should take a different diabetes
medication?
Probes: In your view, are there downsides of taking this
diabetes medication?
What are the positive sides of taking this diabetes
medication?
(17) Did you decide to take a new diabetes medication?
Probe: Why? Why not?
Did you participate in the decision to the extent that you
wanted?
(18) Medications can be quite expensive. Did you look at
the cost card?
Probes: How do you usually discuss the cost of your
medications with your clinician?
(19) [Action] Diabetes medications can influence your
weight loss or gain. Did you look at the weight card?
Probe: How do you usually discuss weight issues with
your clinician?
(INTERVENTION) We also hope to understand how
this tool may influence your clinic appointment.
(20) [interaction] Looking back, do you think that using
the diabetes cards changed your clinic visit in any way? If
so, how?
Probes: Were you able to accomplish what you had
hoped to do during this visit?
(21) [coherence/interaction] How would you describe
your relationship with your clinician?
Probe: Would you say that using the diabetes cards
affected your relationship with your clinican? If so, how?
Explain.
(21a) Did you feel that you got adequate information
from your clinician about diabetes medications and their
potential risks and benefits? How so?
(21b) Did you feel that your clinician took more/less time
to talk to you? Explain. (Visit lasted about XX minutes)
(22) Would you say you have changed anything about
how you take care of yourself since you came to see your
doctor in DATE?
Probe: If yes, what have you changed?
If no, do you plan to change anything about how you
take care of yourself? What?
(23) [social network] Would you recommend using the
diabetes cards to your friends and family?
Probes: Why? Why not?
What would you tell them about the cards?
Your clinician gave you a brochure. Did you show them
the brochure your clinician gave you?
(24) [appraisal] Is there any way you regret using the
diabetes cards during your clinic visit? Explain.
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Probe: Would you have wished the visit would have
gone differently? Explain.
(25) Is there anything you would like to add? Any topics,
you feel, I should have addressed?
Thank you for your time. You can now choose between
these two cookbooks as a little gift for your participation in
this study…
Follow-up: We plan to call you again in a few months
for a follow-up over the phone. Is that okay?
Please feel free to contact the Mayo Clinic study coor-
dinator or myself if you have any questions about this study.
My Mayo phone: 507-XXX-XXXX
Appendix B. 2- and 6-month-patient surveys
Tables 4, 5
References
1. A.R. Weil, The patient engagement imperative. Health Aff. 35(4),
563 (2016)
2. K.L. Carman, P. Dardess, M. Maurer, S. Sofaer, K. Adams, C.
Bechtel, J. Sweeney, Patient and family engagement: a framework







At the time you enrolled in the study, you decided to start taking a diabetes medicine,
are you still taking this medicine?
Missing 117 (72.7%) 147 (77.8%) 264 (75.4%)
Yes 34 (21.1%) 36 (19.0%) 70 (20.0%)
No 10 (6.2%) 6 (3.2%) 16 (4.6%)
At the time you enrolled in the study, you decided not to begin a new diabetes
medicine. Are you taking a new medicine at this time?
Missing 95 (59.0%) 126 (66.7%) 221 (63.1%)
Yes 12 (7.5%) 15 (7.9%) 27 (7.7%)
No 54 (33.5%) 48 (25.4%) 102 (29.1%)
What was the main reason for stopping this medicine?
Missing 148 (91.9%) 177 (93.7%) 325 (92.9%)
Cost 0 (0.0%) 2 (1.1%) 2 (0.6%)
Side effects 5 (3.1%) 2 (1.1%) 7 (2.0%)
Feel fine 0 (0.0%) 1 (0.5%) 1 (0.3%)
Trouble filling Rx 1 (0.6%) 1 (0.5%) 2 (0.6%)
Can’t remember
to take
2 (1.2%) 1 (0.5%) 3 (0.9%)
Other reason 5 (3.1%) 5 (2.6%) 10 (2.9%)
If you are taking a diabetes medication, how many medications do you think you
missed within the last week?
Missing 60 (37.3%) 94 (49.7%) 154 (44.0%)
0 76 (47.2%) 69 (36.5%) 145 (41.4%)
1 10 (6.2%) 11 (5.8%) 21 (6.0%)
1.5 0 (0.0%) 1 (0.5%) 1 (0.3%)
2 7 (4.3%) 8 (4.2%) 15 (4.3%)
3 7 (4.3%) 6 (3.2%) 13 (3.7%)
6 1 (0.6%) 0 (0.0%) 1 (0.3%)
How would you rate your health?
Missing 46 (28.6%) 84 (44.4%) 130 (37.1%)
Excellent 3 (1.9%) 2 (1.1%) 5 (1.4%)
Very good 24 (14.9%) 25 (13.2%) 49 (14.0%)
Good 58 (36.0%) 49 (25.9%) 107 (30.6%)
3.5 1 (0.6%) 0 (0.0%) 1 (0.3%)
Fair 28 (17.4%) 22 (11.6%) 50 (14.3%)
Poor 1 (0.6%) 7 (3.7%) 8 (2.3%)







At the time you enrolled in the study, you decided to start taking a
diabetes medicine, are you still taking this medicine?
Missing 126 (78.3%) 154 (81.5%) 280 (80.0%)
Yes 25 (15.5%) 27 (14.3%) 52 (14.9%)
No 10 (6.2%) 8 (4.2%) 18 (5.1%)
At the time you enrolled in the study, you decided not to begin a new
diabetes medicine. Are you taking a new diabetes medicine at
this time?
Missing 93 (57.8%) 126 (66.7%) 219 (62.6%)
Yes 27 (16.8%) 18 (9.5%) 45 (12.9%)
No 41 (25.5%) 45 (23.8%) 86 (24.6%)
If stopped, what was the main reason for stopping this medicine?
Missing 149 (92.5%) 178 (94.2%) 327 (93.4%)
Cost 1 (0.6%) 2 (1.1%) 3 (0.9%)
Side effects 4 (2.5%) 3 (1.6%) 7 (2.0%)
Can’t remember
to take
1 (0.6%) 1 (0.5%) 2 (0.6%)
Other reason 6 (3.7%) 5 (2.6%) 11 (3.1%)
How many diabetes medicines do you think you missed within the
last week?
Missing 66 (41.0%) 92 (48.7%) 158 (45.1%)
0 73 (45.3%) 71 (37.6%) 144 (41.1%)
1 11 (6.8%) 13 (6.9%) 24 (6.9%)
2 8 (5.0%) 5 (2.6%) 13 (3.7%)
≥3 3 (1.8%) 8 (4.1%) 11 (3.3%)
How would you rate your health?
Missing 54 (33.5%) 88 (46.6%) 142 (40.6%)
Excellent 1 (0.6%) 3 (1.6%) 4 (1.1%)
Very good 24 (14.9%) 25 (13.2%) 49 (14.0%)
Good 59 (36.6%) 45 (23.8%) 104 (29.7%)
Fair 23 (14.3%) 24 (12.7%) 47 (13.4%)
Poor 0 (0.0%) 4 (2.1%) 4 (1.1%)
Have you used these cards with your clinician?
Missing 109 (67.7%) 127 (67.2%) 236 (67.4%)
Yes, one time 1 (0.6%) 8 (4.2%) 9 (2.6%)
Yes, more than
one time
2 (1.2%) 4 (2.1%) 6 (1.7%)






55.2 (51.1, 59.2) 52.7 (49.9,
55.6)
Endocrine
for understanding the elements and developing interventions and
policies. Health Aff. 32(2), 223–231 (2013)
3. M.J. Barry, S. Edgman-Levitan, Shared decision making–pinnacle
of patient-centered care. N. Engl. J. Med. 366(9), 780–781 (2012)
4. M. Kunneman, V.M. Montori, A. Castaneda-Guarderas, E. Hess,
What is shared decision making? (and what it is not). Acad.
Emerg. Med. 23(12), 1320–1234 (2016)
5. I. Hargraves, A. LeBlanc, N.D. Shah, V.M. Montori, Shared
decision making: the need for patient-clinician conversation, not
just information. Health Aff. 35(4), 627–629 (2016)
6. D. Stacey, F. Legare, K. Lewis, M.J. Barry, C.L. Bennett, K.B.
Eden, M. Holmes-Rovner, H. Llewellyn-Thomas, A. Lyddiatt, R.
Thomson, L. Trevena, Decision aids for people facing health
treatment or screening decisions. Cochrane Database Syst. Rev. 4,
CD001431 (2017)
7. C.L. Zeballos-Palacios, I.G. Hargraves, P.A. Noseworthy, M.E.
Branda, M. Kunneman, B. Burnett, M.R. Gionfriddo, C.J.
McLeod, H. Gorr, J.P. Brito, V.M. Montori, Shared decision
making for atrial fibrillation trial I. developing a conversation aid
to support shared decision making: reflections on designing
anticoagulation choice. Mayo Clin. Proc. 94(4), 686–696 (2019)
8. V.M. Montori, M. Kunneman, J.P. Brito, Shared decision making
and improving health care: the answer is not in. JAMA 318(7),
617–618 (2017)
9. M. Breslin, R.J. Mullan, V.M. Montori, The design of a decision
aid about diabetes medications for use during the consultation
with patients with type 2 diabetes. Patient Educ. Couns. 73(3),
465–472 (2008)
10. R.J. Mullan, V.M. Montori, N.D. Shah, T.J. Christianson, S.C.
Bryant, G.H. Guyatt, L.I. Perestelo-Perez, R.J. Stroebel, B.P.
Yawn, V. Yapuncich, M.A. Breslin, L. Pencille, S.A. Smith, The
diabetes mellitus medication choice decision aid: a randomized
trial. Arch. Intern Med. 169(17), 1560–1568 (2009)
11. M.E. Branda, A. LeBlanc, N.D. Shah, K. Tiedje, K. Ruud, H. Van
Houten, L. Pencille, M. Kurland, B. Yawn, V.M. Montori, Shared
decision making for patients with type 2 diabetes: a randomized
trial in primary care. BMC Health Serv. Res. 13, 301 (2013)
12. D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R.
Holman, R. Sherwin, B. Zinman, American Diabetes A, European
Association for Study of D. Medical management of hypergly-
cemia in type 2 diabetes: a consensus algorithm for the initiation
and adjustment of therapy: a consensus statement of the American
Diabetes Association and the European Association for the Study
of Diabetes. Diabetes Care 32(1), 193–203 (2009)
13. O’Connor A. User manual _ knowledge [document on the inter-
net]. (2000). http://decisionaid.ohri.ca/docs/develop/User_Manua
ls/UM_Knowledge.pdf
14. A.M. O’Connor, Validation of a decisional conflict scale. Med
Decis. Mak. 15(1), 25–30 (1995)
15. G. Elwyn, H. Hutchings, A. Edwards, F. Rapport, M. Wensing,
W.Y. Cheung, R. Grol, The OPTION scale: measuring the extent
that clinicians involve patients in decision-making tasks. Health
Expect. 8(1), 34–42 (2005)
16. K.D. Wyatt, M.E. Branda, R.T. Anderson, L.J. Pencille, V.M.
Montori, E.P. Hess, H.H. Ting, A. LeBlanc, Peering into the black
box: a meta-analysis of how clinicians use decision aids during
clinical encounters. Implement Sci. 9, 26 (2014)
17. L.M. Hess, M.A. Raebel, D.A. Conner, D.C. Malone, Measure-
ment of adherence in pharmacy administrative databases: a pro-
posal for standard definitions and preferred measures. Ann.
Pharmacother. 40(7-8), 1280–1288 (2006)
18. C. May, T. Finch, Implementing, embedding, and integrating
practices: an outline of normalization process theory. Sociology
43(3), 535–554 (2009)
19. C.R. May, A. Cummings, M. Girling, M. Bracher, F.S. Mair, C.
M. May, E. Murray, M. Myall, T. Rapley, T. Finch, Using Nor-
malization Process Theory in feasibility studies and process eva-
luations of complex healthcare interventions: a systematic review.
Implement. Sci. 13(1), 80 (2018)
20. S.V. Edelman, W.H. Polonsky, Type 2 diabetes in the real world:
the elusive nature of glycemic control. Diabetes Care 40(11),
1425–1432 (2017)
21. A. Donner, N.S. Klar. Design and Analysis of Cluster Randomi-
sation Trials in Health Research. (Hodder Arnold, London, 2000)
22. SAS Institute Inc. SAS® 9.4 Statements: Reference. (Cary, NC:
SAS Institute Inc, 2013)
23. StataCorp. Stata Statistical Software: Release 14. (College Sta-
tion, TX: StataCorp LP, 2015)
24. A. Towle, W. Godolphin, Framework for teaching and learning
informed shared decision making. BMJ 319(7212), 766–771
(1999)
25. American Diabetes A. 10, Cardiovascular disease and risk man-
agement: standards of medical care in diabetes-2019. Diabetes
Care 42(Suppl 1), S103–S123 (2019)
26. American Diabetes A. 6, Glycemic targets: standards of medical
care in diabetes-2019. Diabetes Care 42(Suppl 1), S61–S70
(2019)
27. S.A. Hartasanchez, A.F. Heen, M. Kunneman, A. Garcia-Bautista,
I.G. Hargraves, L.J. Prokop, C.R. May, V.M. Montori. Remote
shared decision making through telemedicine: a systematic review
of the literature. Patient Educ. Couns. S0738-3991(21)00411-0
(2021). https://doi.org/10.1016/j.pec.2021.06.012 [Online ahead
of print]
28. N.T. Diouf, A. Ben Charif, L. Adisso, R. Adekpedjou, H.T.V.
Zomahoun, T.T. Agbadje, M.J. Dogba, M.M. Garvelink, Shared
decision making in West Africa: The forgotten area. Z. Evid.
Fortbild. Qual. Gesundhwes 123-124, 7–11 (2017)
29. R. Nieuwlaat, N. Wilczynski, T. Navarro, N. Hobson, R. Jeffery,
A. Keepanasseril, T. Agoritsas, N. Mistry, A. Iorio, S. Jack, B.
Sivaramalingam, E. Iserman, R.A. Mustafa, D. Jedraszewski, C.
Cotoi, R.B. Haynes, Interventions for enhancing medication
adherence. Cochrane Database Syst. Rev. 11, CD000011 (2014)




31. G. Spencer-Bonilla, R. Rodriguez-Gutierrez, V.M. Montori,
Minimally disruptive diabetes care for the elderly. Diabetes
Technol. Ther. 18(12), 759–761 (2016)
32. M. Kunneman, F.R. Gärtner, I.G. Hargraves, V.M. Montori,
Commentary on “The stereotypicality of symptomatic and prag-
matic argumentation in consultations about palliative systemic
treatment for advanced cancer”. J. Argumentation Context 7(2),
205–209 (2018)
33. I.G. Hargraves, V.M. Montori, J.P. Brito, M. Kunneman, K.
Shaw, C. LaVecchia, M. Wilson, L. Walker, B. Thorsteinsdottir,
S.D.M. Purposeful, A problem-based approach to caring for
patients with shared decision making. Patient Educ. Couns. 102
(10), 1786–1792 (2019)
34. C. May, V.M. Montori, F.S. Mair, We need minimally disruptive
medicine. BMJ 339, b2803 (2009)
Endocrine
Affiliations
Marleen Kunneman 1,2 ● Megan E. Branda1,3,4 ● Jennifer L. Ridgeway5 ● Kristina Tiedje6 ● Carl R. May7 ●
Mark Linzer8 ● Jonathan Inselman5,9 ● Angela L. H. Buffington10,11 ● Jordan Coffey12,13 ● Deborah Boehm14,15,16 ●
James Deming17 ● Sara Dick1 ● Holly van Houten5 ● Annie LeBlanc1,18 ● Juliette Liesinger5,9 ● Janet Lima19 ●
Joanne Nordeen20 ● Laurie Pencille1,21 ● Sara Poplau22 ● Steven Reed23 ● Anna Vannelli19 ● Kathleen J. Yost24 ●
Jeanette Y. Ziegenfuss25,26 ● Steven A. Smith27 ● Victor M. Montori1 ● Nilay D. Shah9,5
1 Knowledge and Evaluation Research Unit, Division of
Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo
Clinic, Rochester, MN, USA
2 Medical Decision Making, Department of Biomedical Data
Sciences, Leiden University Medical Center, Leiden, The
Netherlands
3 Department of Biostatistics and Informatics, Colorado School of
Public Health, University of Colorado-Denver Anschutz Medical
Campus, Aurora, CO, USA
4 Division of Biomedical Statistics and Informatics, Department of
Health Sciences Research, Mayo Clinic, Rochester, MN, USA
5 Division of Health Care Policy and Research, Department of
Health Sciences Research, Mayo Clinic, Rochester, MN, USA
6 Laboratoire d’anthropologie des enjeux contemporains,
Lyon, France
7 Faculty of Public Health and Policy, London School of Hygiene
and Tropical Medicine, London, UK
8 Department of Medicine, Hennepin Healthcare and University of
Minnesota, Minneapolis, MN, USA
9 Mayo Clinic Robert D. and Patricia E. Kern Center for the Science
of Health Care Delivery, Rochester, MN, USA
10 Department of Psychiatry and Psychology, Mayo Clinic Health
System, Mankato, MN, USA
11 Department of Family Medicine and Community Health,
University of Minnesota Medical School, Minneapolis, MN, USA
12 Practice-Based Research Network, Mayo Clinic, Rochester, MN,
US
13 Center for Translational Science Activities, Mayo Clinic,
Rochester, MN, USA
14 Center for Patient and Provider Experience, Hennepin County
Medical Center, Minneapolis, MN, USA
15 School of Nursing, University of Minnesota, Minneapolis, MN,
USA
16 Decision Partners for Health, Richfield, MN, USA
17 Mayo Clinic Health System Northwest Wisconsin, (dept) Home
Health and Hospice, Eau Claire, WI, USA
18 Department of Family and Emergency Medicine, Faculty of
Medicine, Laval University, Quebec, QC, Canada
19 Park Nicollet International Diabetes Center, St. Louis Park, MN,
USA
20 Mayo Clinic Health System, La Crosse, WI, US
21 Kern Center for the Science of Health Care Deliver, Mayo Clinic,
Rochester, MN, USA
22 Office of Professional Worklife, Hennepin Healthcare,
Minneapolis, MN, USA
23 Department of Internal Medicine, Park Nicollet Clinic,
Brooklyn Center, MN, USA
24 Division of Epidemiology, Department of Health Sciences
Research, Mayo Clinic, Rochester, MN, USA
25 Division of Health Sciences Research, Mayo Clinic,
Rochester, MN, USA
26 Center for Evaluation and Survey Research, HealthPartners
Institute, Bloomington, USA
27 Division of Endocrinology, Diabetes, Metabolism, and Nutrition,
Mayo Clinic, Rochester, MN, USA
Endocrine
